{
    "clinical_study": {
        "@rank": "124224", 
        "arm_group": [
            {
                "arm_group_label": "LPV/r", 
                "description": "LPV/r based HAART"
            }, 
            {
                "arm_group_label": "Efavirenz", 
                "description": "EFV first line based HAART"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate changes in Framingham score (from low to\n      moderate, from moderate to high) based on changes in lipid profile and other parameters from\n      baseline to 48 weeks of HAART in na\u00efve patients or  patients in second line of treatment,\n      considering LPV/r vs EFV based HAART. The null hyphotesis is that there is an increased\n      Framingham score  in patients treated with LPV/r as second line  treatment and in patients\n      treated with LPV/r or EFV regimen as first line treatments."
        }, 
        "brief_title": "Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV", 
            "Hypercholesterolemia", 
            "Dyslipidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Dyslipidemias"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study design and duration: Retrospective comparative study. Estimated time of enrollment: 12\n      months.\n\n      Procedure: Retrospective review of clinical charts:  LPV/r (n = 100) and EFV (a randomly\n      selected representative sample of patients under EFV treatment: 200 patients\n      approximately.). Each patient can only be included in one arm of the study (cannot switch\n      EFV to LPV/r or from LPV/r to EFV)\n\n      Subject population\n\n      LPV/r (n = 100) and EFV (a randomly selected representative sample of patients under EFV\n      treatment: 200 patients approximately.). Each patient can only be included in one arm of the\n      study (cannot switch EFV to LPV/r or from LPV/r to EFV)\n\n      Study Objectives:\n\n      Primary Objectives\n\n      1)Changes in Framingham score (from low to moderate, from moderate to high) based on changes\n      in lipid profile and other parameters from baseline to 48 weeks of HAART  in na\u00efve patients\n      or  patients in second line  of treatment Secondary Objectives\n\n        1. Risk assessment hazard of CV events in HIV- infected subjects treated with a LPV/r as\n           second line and EFV and LPV/r first line based HAART regimen in the whole population\n           under study and in the female and male subpopulations.\n\n        2. Assessment for 10- year risk of developing hard cardiovascular events  (myocardial\n           infarction and coronary death) in HIV- infected subjects treated with a LPV/r ( 1\u00b0 o 2\u00b0\n           line) and  EFV first line based HAART regimen\n\n        3. Overall mortality (including CV events) in HIV- infected subjects  treated with a LPV/r\n           as second line and EFV and LPV/r first line based HAART regimen\n\n        4. Evolution of lipid profile (total cholesterol, HDL, LDL and triglicerides) and lipid\n           lowering agents requirement: baseline vs. 48 weeks after the initiation of a LPV/r\n           second line based HAART regimen and those on an LPV/r and EFV first line based HAART\n           regimen\n\n        5. Assesment of  CD4 T-cell count and viral load at baseline and at 48 weeks in each\n           regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. HIV positive patients (confirmation with ELISA + W. blot required).\n\n          2. Age \u2265 18 years.\n\n          3. Na\u00efve or experienced with antiretroviral drugs.\n\n          4. LPV/r or EFV as first line regimen.\n\n          5. In patients with a LPV/r second line HAART regimen, prior exposure to any NNRTI\n             regimen is acceptable.\n\n          6. Time of exposure to LPV/r  or EFV of at least 48 weeks.\n\n        Exclusion criteria:\n\n          1. Age < 18 yrs.\n\n          2. Already LPV/r treatment at admission in our institution (that prevents assessment of\n             baseline lipid profile and CV risk when patient receives the \"first dose\" of either\n             LPV/r )\n\n          3. Patients that had received LPV/r only during they pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "HIV-infected patients with first line HAART with EFV or LPV/r or second line HAART with\n        LPV/r"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705873", 
            "org_study_id": "ANV-10-0165"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "cardiovascular", 
            "risk", 
            "mortality"
        ], 
        "lastchanged_date": "October 11, 2012", 
        "location": {
            "contact": {
                "email": "dcecchini@heliossalud.com.ar", 
                "last_name": "Diego M Cecchini, PhD", 
                "phone": "54 11 4896 1868", 
                "phone_ext": "116"
            }, 
            "facility": {
                "address": {
                    "city": "Buenos Aires", 
                    "country": "Argentina", 
                    "zip": "1141"
                }, 
                "name": "Helios Salud"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Argentina"
        }, 
        "number_of_groups": "2", 
        "official_title": "Retrospective Analysis on the Risk of Cardiovascular (CV) Events in HIV- Infected Subjects From Latin America Treated With a Lopinavir/Ritonavir (LPV/r) Based HAART Regimen vs. an Efavirenz (EFV) Based HAART Regimen", 
        "other_outcome": [
            {
                "description": "Evolution of lipid profile (total cholesterol, HDL, LDL and triglicerides) and lipid lowering agents requirement from baseline at 6, 12, Q12 months after the initiation of a LPV/r  second line based HAART regimen and those on an LPV/r or EFV first line based HAART regimen in the whole population under study. Participants will be followed for an average of 24 months .", 
                "measure": "Evolution of lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Per year"
            }, 
            {
                "description": "Evolution of lipid profile (total cholesterol, HDL, LDL and triglicerides) and lipid lowering agents requirement from baseline at 6, 12, Q12 months after the initiation of a LPV/r  second line based HAART regimen and those on an LPV/r or EFV first line based HAART regimen in male subpopulation. Participants will be followed for an average of 24 months .", 
                "measure": "Evolution of lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Per year"
            }, 
            {
                "description": "Evolution of lipid profile (total cholesterol, HDL, LDL and triglicerides) and lipid lowering agents requirement from baseline at 6, 12, Q12 months after the initiation of a LPV/r  second line based HAART regimen and those on an LPV/r or EFV first line based HAART regimen in female subpopulation. Participants will be followed for an average of 24 months .", 
                "measure": "Evolution of lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Per year"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Helios Salud", 
                "last_name": "Lidia I Cassetti, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Helios Salud", 
                "last_name": "Diego M Cecchini, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Argentina: Human Research Bioethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Changes in Framingham risk for CV events (from low to moderate, from moderate to high) based on changes in lipid parameters from baseline at 6, 12, Q12 months after the initiation of a LPV/r based HAART regimen in the whole population under study.Participants will be followed for an average of 24 months .", 
                "measure": "Risk for CV events", 
                "safety_issue": "Yes", 
                "time_frame": "Per year"
            }, 
            {
                "description": "Changes in Framingham risk for CV events (from low to moderate, from moderate to high) based on changes in lipid parameters from baseline at 6, 12, Q12 months after the initiation of a LPV/r based HAART regimen in male subpopulation.Participants will be followed for an average of 24 months .", 
                "measure": "Risk for CV events", 
                "safety_issue": "Yes", 
                "time_frame": "Per year"
            }, 
            {
                "description": "Changes in Framingham risk for CV events (from low to moderate, from moderate to high) based on changes in lipid parameters from baseline at 6, 12, Q12 months after the initiation of a LPV/r based HAART regimen in female subpopulation. Participants will be followed for an average of 24 months .", 
                "measure": "Risk for CV events", 
                "safety_issue": "Yes", 
                "time_frame": "Per year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705873"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Helios Salud", 
            "investigator_full_name": "Isabel Cassetti", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall mortality (including CV events) in HIV- infected subjects  treated with a LPV/r as second line and EFV and LPV/r first line based HAART regimen in the whole population under study. Participants will be followed for an average of 24 months .", 
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Per year"
            }, 
            {
                "description": "Overall mortality (including CV events) in HIV- infected subjects  treated with a LPV/r as second line and EFV and LPV/r first line based HAART regimen in male subpopulation.Participants will be followed for an average of 24 months .", 
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Per year"
            }, 
            {
                "description": "Overall mortality (including CV events) in HIV- infected subjects  treated with a LPV/r as second line and EFV and LPV/r first line based HAART regimen in female subpopulation. Participants will be followed for an average of 24 months .", 
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Per year"
            }
        ], 
        "source": "Helios Salud", 
        "sponsors": {
            "collaborator": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Helios Salud", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}